Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Liu TM, et al. Among authors: maddocks k. Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13. Blood. 2015. PMID: 25972157 Free PMC article.
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Croce CM, Byrd JC, Johnson AJ. Hertlein E, et al. Blood. 2010 Jul 8;116(1):45-53. doi: 10.1182/blood-2010-01-263756. Epub 2010 Mar 29. Blood. 2010. PMID: 20351313 Free PMC article.
Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies.
Mahoney E, Maddocks K, Flynn J, Jones J, Cole SL, Zhang X, Byrd JC, Johnson AJ. Mahoney E, et al. Among authors: maddocks k. Leuk Lymphoma. 2013 Dec;54(12):2685-92. doi: 10.3109/10428194.2013.781168. Epub 2013 Apr 16. Leuk Lymphoma. 2013. PMID: 23469959 Free PMC article.
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM. Stephens DM, et al. Among authors: maddocks k. Leuk Res. 2013 Oct;37(10):1195-9. doi: 10.1016/j.leukres.2013.06.006. Epub 2013 Jul 15. Leuk Res. 2013. PMID: 23867058 Free PMC article. Clinical Trial.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Dubovsky JA, et al. Among authors: maddocks k. Blood. 2013 Oct 10;122(15):2539-49. doi: 10.1182/blood-2013-06-507947. Epub 2013 Jul 25. Blood. 2013. PMID: 23886836 Free PMC article. Clinical Trial.
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.
Zhong Y, El-Gamal D, Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, Goettl VM, Jha S, Mo X, Jones JA, Flynn JM, Maddocks KJ, Andritsos LA, McCauley D, Shacham S, Kauffman M, Byrd JC, Lapalombella R. Zhong Y, et al. Among authors: maddocks kj. Leukemia. 2014 May;28(5):1158-63. doi: 10.1038/leu.2014.9. Epub 2014 Jan 13. Leukemia. 2014. PMID: 24413321 Free PMC article. No abstract available.
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. Woyach JA, et al. Among authors: maddocks k. Blood. 2014 Mar 20;123(12):1810-7. doi: 10.1182/blood-2013-09-527853. Epub 2014 Jan 10. Blood. 2014. PMID: 24415539 Free PMC article.
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N. Beckwith KA, et al. Among authors: maddocks kj. Leukemia. 2014 Jul;28(7):1501-10. doi: 10.1038/leu.2014.32. Epub 2014 Jan 21. Leukemia. 2014. PMID: 24445867 Free PMC article.
Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. Stephens DM, et al. Among authors: maddocks k. Leukemia. 2014 Jun;28(6):1365-8. doi: 10.1038/leu.2014.42. Epub 2014 Jan 23. Leukemia. 2014. PMID: 24451411 Free PMC article. Clinical Trial. No abstract available.
Ibrutinib in B-cell Lymphomas.
Maddocks K, Blum KA. Maddocks K, et al. Curr Treat Options Oncol. 2014 Jun;15(2):226-37. doi: 10.1007/s11864-014-0274-8. Curr Treat Options Oncol. 2014. PMID: 24481980 Review.
132 results